Most methods for the detection of nucleic acids require many reagents and expensive and bulky instrumentation. Here, we report the development and testing of a graphene-based field-effect transistor that uses clustered regularly interspaced short palindromic repeats (CRISPR) technology to enable the digital detection of a target sequence within intact genomic material. Termed CRISPR-Chip, the biosensor uses the gene-targeting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a specific single-guide RNA and immobilized on the transistor to yield a label-free nucleic-acid-testing device whose output signal can be measured with a simple handheld reader. We used CRISPR-Chip to analyse DNA samples collected from HEK293T cell lines expressing blue fluorescent protein, and clinical samples of DNA with two distinct mutations at exons commonly deleted in individuals with Duchenne muscular dystrophy. In the presence of genomic DNA containing the target gene, CRISPR-Chip generates, within 15 min, with a sensitivity of 1.7 fM and without the need for amplification, a significant enhancement in output signal relative to samples lacking the target sequence. CRISPR-Chip expands the applications of CRISPR-Cas9 technology to the on-chip electrical detection of nucleic acids. The power of the CRISPR-Chip system is due to the combination of its two main components: the dRNP and the graphene. The immobilized dRNP is not only sequence specific, but also programmable. For example, to expand the scope of CRISPR-Chip analysis to a wide variety of genes, the target-specific 20-nucleotide sequence of the sgRNA within the dRNP construct can be simply modified at the 5′ end 15 . The graphene, with a high carrier mobility (> 2,000 cm 2 Vs −1
I
n recent years, whole-genome sequencing has allowed for the broad analysis and identification of biomarkers indicative of various pathologies [1] [2] [3] . This expanded knowledge has allowed for the development of various target-specific nucleic acid detection tools [4] [5] [6] . Such tools hold the power to provide physicians with actionable information to improve patient outcomes and introduce precise medical treatment approaches. Most established methods for nucleic acid-based molecular diagnostic tests, such as PCR, have been optimized over the past 30 years to amplify and detect targeted genome sequences 7, 8 . Despite significant advancement in nucleic acid detection technologies, the majority of these nucleic acid detection tools are time consuming and costly to use, as they require multi-step reactions, many reagents, trained personnel and complex instrumentation. In addition, quantitative analysis of these nucleic acid amplification techniques often requires sophisticated probe/primer design and optimization methodologies for efficient targeting. Furthermore, they often still rely on large and expensive optical components for detection 9, 10 . Therefore, new methodologies are needed to overcome the limitations associated with conventional nucleic acid detection strategies to afford low-cost and fully integrated compact nucleic acid-based diagnostic tools to expand their clinical utility.
In recent studies, clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease (Cas)-based methodologies have been utilized to improve on conventional nucleic acid targeting for optical detection [11] [12] [13] . CRISPR-Cas proteins, guided by a single-stranded RNA, are a powerful tool for sequence-specific targeting and detection. For example, in 2017, Gootenberg et al. 11 reported the development of the SHERLOCK methodology, which utilized an RNA-guided RNA targeting Cas13a (CRISPR-associated nuclease 13a) to provide a fluorescent signal readout after Cas13a complex hybridization with its target sequence, once initially amplified by recombinase polymerase amplification (RPA). Soon after, the HOLMES methodology was reported by Li et al. 12 , which utilized a DNA-targeting Cas12a to eliminate the need for the DNA to RNA conversion required by SHERLOCK for DNA sequence detection. Both SHERLOCK and HOLMES allowed for the sequencespecific detection of DNA and RNA via collateral cleavage of a single-stranded nucleic acid probe post-amplification 14 . Due to the programmability of CRISPR-Cas RNA guides 15 , these methodologies are easily modified to detect different targets. However, they still rely on initial amplification steps via RPA and T7 transcription, resulting in added time and reagents.
Here, we report the design and construction of a CRISPRenhanced graphene-based field-effect transistor (gFET) termed CRISPR-Chip. This biosensor combines the gene-targeting capacity of CRISPR-Cas9 with the sensitive detection power of a gFET 16, 17 to afford the facile, rapid and selective detection of a target sequence contained within intact genomic DNA (Fig. 1) . CRISPR-Chip, a three-terminal gFET, uses functionalized graphene as a channel between the source and drain electrodes. The graphene is functionalized with a catalytically deactivated Cas9 (dCas9) CRISPR complex, denoted as dRNP, which interacts with its target sequence by scanning the whole genomic sample, unzipping the double helix and associating upstream of a protospacer adjacent motif 18 until it finds and binds to the target sequence that is complementary to the single-guide RNA molecule (sgRNA) within the dRNP 19, 20 . The selective hybridization of the target DNA to the dRNP complex
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modulates the electrical characteristics of the gFET and results in an electrical signal output.
The power of the CRISPR-Chip system is due to the combination of its two main components: the dRNP and the graphene. The immobilized dRNP is not only sequence specific, but also programmable. For example, to expand the scope of CRISPR-Chip analysis to a wide variety of genes, the target-specific 20-nucleotide sequence of the sgRNA within the dRNP construct can be simply modified at the 5′ end 15 . The graphene, with a high carrier mobility (> 2,000 cm 2 Vs
) is sensitive to the adsorption and interaction of charged molecules at its surface 21 . Thus, the hybrid graphene-CRISPR construct of CRISPR-Chip makes it an ideal candidate for next-generation nucleic acid biosensors.
A schematic of the gFET construct of CRISPR-Chip is shown in Fig. 2a . CRISPR-Chip utilizes a liquid-gate electrode, which is in constant contact with the genomic sample contained within the reaction buffer. The applied voltage between the liquid-gate and source electrodes (V g ) controls the current flowing between the source and the drain electrodes of the graphene channel. The hybridization of the negatively charged DNA target and immobilized dRNPs on the surface of the graphene channel not only alters the channel conductivity, but also creates an ion-permeable layer atop the graphene surface due to an accumulation of counter ions to maintain charge neutrality. This difference in the concentration of ions between the bulk solution and the immobilized ion-permeable layer creates a Donnan potential 22, 23 . This additional potential results in an alteration in the electric field between the source and the gate electrodes, resulting in further modulation of the graphene channel current, enabling sensing beyond the Debye screening length [24] [25] [26] . A detailed description of the device operation and measurement method is provided in the Supplementary Information (Device Operation, Measurement Description and Supplementary Figs. 1-6 ).
CRISPR-Chip is fabricated in several stages using conventional microelectromechanical systems 27 processing and is then functionalized according to the scheme shown in Fig. 2b . Briefly, after fabrication and packaging, the chips are cleaned, and noncovalently functionalized with the molecular linker, 1-pyrenebutanoic acid (PBA), via π-π aromatic stacking 21 . Then, dCas9 is immobilized on the surface of the graphene channel via carbodiimide crosslinking chemistry 28, 29 . dCas9 immobilization is then followed by surface blocking, with amino-PEG5-alcohol and ethanolamine hydrochloride, to prevent the non-specific adsorption of charged molecules [30] [31] [32] . Finally, the immobilized dCas9 is complexed with a sgRNA, specific to a DNA target, forming the anchored dRNP complex.
Results

Specificity of the immobilized dRNP to its target sequence.
CRISPR-Chip's binding specificity to its target double-stranded DNA (dsDNA) was first evaluated by utilizing a PCR product of the bfp gene, which encodes for blue fluorescent protein, a commonly used gene for CRISPR-Cas gene editing validation 33, 34 . A schematic of this experiment is shown in Fig. 3a , where CRISPR-Chips were functionalized with either dRNPs specific to bfp (dRNP-BFP) or a scramble dRNP specific to the gene pcsk9 (ref. 35 ) (dRNP-Scram), as described above. bfp amplicons were obtained via PCR amplification of genomic DNA from HEK293T cells that had been transfected with a bfp-containing lentivirus 34, 36 . Non-transfected HEK293T cells are referred to as HEK and bfp transfected HEK293T cells are referred to as HEK-BFP cells hereafter. The dRNP-BFP-and dRNP-Scramfunctionalized CRISPR-Chips were calibrated, then incubated with 1800 ng of bfp amplicons. The sensor response was monitored in real-time and the sensor data were analysed according to equation (1) , where I ds is the current between the drain and source electrodes after incubation with the genomic sample and subsequent washing (see Device Operation in the Supplementary Information for the I ds equation) and I ds0 is the calibration baseline signal taken in assay buffer during calibration. This calibration step helps to eliminate the effect of sensor-to-sensor variation in resistance, as well as the effect of the buffer. We utilized percent 'I response' as our unit of measure. I response is the percentage change in I ds (measured after incubation with the sample and the rinsing step) compared with the calibration baseline (I ds0 ).
ds ds0 ds0 Figure 3b shows the I response of the two CRISPR-Chips in the presence of the target bfp sequence. CRISPR-Chip functionalized with dRNPs-BFP presented a significantly larger signal than that of the non-specific dRNP-Scram-functionalized CRISPR-Chips (P = 0.0002). This result indicates that CRISPR-Chip's signal output is specific to the immobilized dRNP complex. Furthermore, the real-time monitoring of the CRISPR-Chip response, shown in Affinity of the immobilized dRNP to its target sequence within intact genomic DNA. The ultimate goal of CRISPR-Chip was to detect its target dsDNA sequence from whole-genome samples. Therefore, we first ensured that immobilized dRNPs were capable of binding and maintaining their affinity to the target sequence within the scale of whole-genome samples. For this experiment, the dRNP-BFP complex was immobilized on the surface of carboxylated magnetic beads (MBs) (1 μm; Invitrogen) with a protocol similar to that of CRISPR-Chip functionalization (Fig. 4a) . Briefly, dCas9 was covalently bound to the carboxylated MBs via carbodiimide crosslinking chemistry, blocked and incubated with sgRNA specific to bfp to form the dRNP-BFP complex on the surface of the MBs. The MBs were then incubated with unamplified whole genomic BFP samples obtained from HEK-BFP cell lysate and subsequently extracted using a magnetic separator. The supernatant, which contained any unbound genomic material, was then evaluated using gel electrophoresis ( Supplementary Figs. 10 ) and the concentration of the genomic material was evaluated pre-and post-incubation with MBs to determine the capture efficiency and the relative affinity of the immobilized dRNPs to their target DNA contained within the whole genome. As a negative control, dRNP-BFP-functionalized MBs where incubated with non-target genomic material obtained from HEK cells. Figure 4b shows that the capture efficiency of the functionalized MBs for the HEK-BFP genomic sample was significantly higher (P = 0.002) than that of the negative control. These results suggest that the interaction between dRNPs and their target sequences within the full-scale genomic DNA was maintained during the physical force of washing and pipetting when anchored to a surface.
CRISPR-Chip capacity for the detection of non-amplified target sequence in the absence and presence of genomic contamination.
Next, we investigated CRISPR-Chip's ability to detect whole-genome samples containing the bfp target. The selection of this genomic BFP model was based on of the experimental evidence collected from the aforementioned PCR model, which demonstrated that the dRNP-BFP-functionalized CRISPR-Chip was able to specifically detect bfp amplicons. To investigate CRISPR-Chip ability to detect the bfp gene within whole-genome samples, dRNP-BFP-functionalized CRISPRChips were fabricated and evaluated in the presence of varying concentrations of the target HEK-BFP genomic samples (300-1,200 ng). For control experiments, dRNP-BFP-functionalized CRISPR-Chips were incubated with 900 ng of HEK genomic sample, which lacked the bfp gene. A schematic of this experiment is shown in Fig. 5a . Figure 5b shows that CRISPR-Chip generated a significant enhancement (P = 0.0002) in signal output after exposure to 900 ng of its target genomic material relative to control samples lacking the target sequence. Figure 5c indicates the sensitivity of CRISPR-Chip for the detection of HEK-BFP, and Fig. 5d shows real-time monitoring of the I response with varying concentrations of HEK-BFP. These results indicate a limit of detection (LOD) of 2.3 fM. In addition, the real-time monitoring of the I response indicates that after CRISPR-Chip incubation with genomic samples, the signal reached its saturation within 5 min, showing that this incubation time was sufficient, before rinsing the sensor to remove unbound genomic material, to obtain the final I response. Therefore, the total analysis time required for CRISPR-Chip (including sample incubation and the rinsing step) can be estimated as 15 min.
We further examined the dRNP-BFP-functionalized CRISPRChip's ability to specifically bind to its target sequence contained within 900 ng HEK-BFP in the presence of varying concentrations (0-1,800 ng) of the non-target HEK genomic DNA (Fig. 5e) . Figure  5f shows the real-time data obtained during this experiment. This result demonstrates that CRISPR-Chip's I response variation in the presence of increasing concentrations of the contaminant DNA was not significant. Figure 5g ,h shows a direct comparison between the CRISPR-Chip I response after incubation with 900 ng of HEK-BFP in the presence and absence of 900 ng of HEK genomic contaminant, showing non-significant variation in the I response (P > 0.05). Figure 5i indicates that PCR yielded a similarly non-significant response to the presence and absence of HEK genomic contaminant (P > 0.05).
CRISPR-Chip clinical utility for the detection of two mutations
within the non-amplified dystrophin gene. To further validate CRISPR-Chip's utility for clinical applications, we analysed its ability of to detect Duchenne muscular dystrophy (DMD)-associated mutations. We selected DMD detection as the first clinical model for CRISPR-Chip application due to recent advancement in gene editing technologies, such as CRISPR-based therapeutics 36, 37 . DMD is caused by an X-linked dystrophin gene mutation, which can occur across all 79 exons with the most frequent being large deletions at exons 2-10 and 45-55 (refs. 38, 39 ). These mutations result in the expression of dysfunctional dystrophin, which is a vital protein for mature muscle fibres and proper function of muscle stem cells 40 . The absence of this functional protein leads to continuous degeneration of muscle tissue, and orthopaedic and respiratory complications, which can lead to high morbidity and mortality in DMD patients 41 . Current methodologies to detect DMD include DNA amplification to screen for commonly known deletions within the dystrophin gene and combination methods of measuring levels of creatine kinase paired with genetic testing 42, 43 . Early and facile diagnosis of DMD-associated mutations in routine clinical practice, before the onset of severe or lethal symptoms, has the potential to improve treatment outcomes, particularly in the age of gene therapy.
CRISPR-Chip's ability to detect DMD-associated mutations was evaluated using two dRNPs, which targeted exons 3 and 51 of the human dystrophin gene. These exons are commonly deleted in patients with DMD 39 . Figure 6a shows a schematic of the exons of the dystrophin gene, with highlighted CRISPR-Chip target exons and PCR primer targets. For DMD analysis, CRISPR-Chips were functionalized with either dRNPs specific to exon 3 (dRNP-DMD3) or dRNPs specific to exon 51 (dRNP-DMD51). Both CRISPRChip constructs were then incubated with 900 ng of tissue-derived genomic material from male DMD patients (Coriell Institute for Medical Research) with an identified mutation in exon 3 or 51 (ref. 44 ). Healthy male genomic samples were obtained from the same vendor and validated for the presence of exon 3 and 51 ( Supplementary  Fig. 14) before being introduced to both CRISPR-Chip constructs. Figure 6b ,c shows that dRNP-DMD3-and dRNP-DMD51-functionalized CRISPR-Chips generated significant enhancement (P ≤ 0.00059) in signal output after exposure to genomic samples containing the target exons 3 or 51, relative to DMD samples carrying deletions at exon 3 or 51. Additional experiments were performed to define a negative signal threshold. For these experiments, CRISPR-Chip's response was evaluated in the presence of the highest concentration of genomic material, obtainable via a commercial buccal sampling method (epMotion 5075 VAC; Eppendorf; 2,800 ng), from patients with an identified mutation in exon 3 or 51 (Fig. 6d) . These experiments allowed for the negative signal threshold to be defined (1.73%), enabling the electrical signal output to be translated to a simple positive or negative result (Fig. 6e) .
The results from this study have important implications in the context of rapid and facile identification of genetic mutations associated with hereditary diseases, specifically those involving large fragment deletions and insertions, such as Huntington's disease and haemophilia B [45] [46] [47] . Figure 6f shows the sensitivity of dRNP-DMD51-functionalized CRISPR-Chip in the presence of DMD genomic sample containing exon 51 (sample A). This result indicates that the minimum quantity of genomic material required for CRISPR-Chip's amplification-free identification of an exon 51 deletion is comparable to the quantity of genomic material obtainable from non-invasive commercial buccal sampling methods (epMotion 5075 VAC (Eppendorf) and the Gentra Puregene Buccal Cell Kit (Qiagen)). The LOD of CRISPR-Chip was found to be 3.3 ng µl ; ~2.9 Gb) 48, 49 , this LOD translated to 1.7 fM genomic material for DMD analysis. This LOD was ), where s b is the standard deviation of the I response of the negative control (2.8 µg of DMD sample A) and m is the slope of the DMD calibration curve (Fig. 6f) .
All of the experiments in these studies were performed with three different CRISPR-Chips for each sample analysed. In addition, CRISPR-Chip reproducibility parameters were further investigated by measuring the relative standard deviation (RSD) obtained from dRNP-DMD51-functionalized CRISPR-Chips (n = 6) after incubation with 700 ng of the same genomic DMD sample A. The results, shown in Fig. 6g , indicate an RSD of 10.6%, which shows good reproducibility for DNA analysis 52 . When performing recovery measurements, an average yield of above 92% was observed (see Supplementary Table 4) , showing that CRISPR-Chip is reliable for quantitative analysis of genomic samples 53, 54 .
Discussion
The discovery of Cas and the development of associated technologies has inspired numerous advancements in the field of gene therapy, due to the capacity of the CRISPR-Cas enzymatic system to perform specific targeting, deletions and insertion in vivo 55, 56 , but these proteins have yet to inspire the same fandom for gene detection applications. We have utilized the catalytically deactivated CRISPR-Cas9 complex as the capture mechanism in this gFET biosensor for rapid identification and quantification of target DNA sequences. gFET biosensors are very attractive for biosensing applications due to their high sensitivity and capability for label-free digital biomolecule detection 31, 57 . In particular, CRISPR-Chip utilizes a liquid-gate gFET and a sweeping gate voltage that can mitigate the limitations associated with charge screening effects and reduced sensitivity of the graphene biosensor to the binding events occurring beyond the Debye length [24] [25] [26] . The RNA-guided dCas9 complex immobilized on the surface of the graphene within in the CRISPRChip gFET construct can specifically bind, enrich and detect the target DNA without the need for reagents and bulky instruments.
The clinical utility of the this first-generation CRISPR-Chip was evaluated for the detection of genetic mutations indicative of DMD. CRISPR-Chip was able to specifically detect the deletion of two target sequences in DMD patients without any pre-amplification. Although CRISPR-Chips were designed to detect only two common DMD exon deletions, these studies indicate that the targeting capacity of CRISPR-Chip can be expanded for multiplex gene analysis by simply modifying the unique 20-nucleotide sequence at the 5′ end of the sgRNA molecule within the dRNP construct. Within the context of DMD, each exon in the dystrophin gene could be targeted to detect disease-causative exon deletions. This proofof-concept evaluation of CRISPR-Chip also indicated a LOD of 1.7 fM in DMD analysis without amplification. These studies show that CRISPR-Chip may bypass the need for sequence amplification for hereditary disease analysis as the genomic material required for CRISPR-Chip analysis is obtainable via commercially available buccal swab methods 58 . The CRISPR-Chip LOD was lower than for previously reported amplification-free technologies for the detection of target sequences contained within the whole genome 6, 59, 60 . Although a method based on plasmon resonance imaging with higher sensitivity has been reported 5 , it requires fragmentation of genomic DNA samples via sonication, multiple DNA probes and bulky optical equipment for sequence-specific detection. A direct comparison between CRISPR-Chip and previously reported technologies is reported in Supplementary Table 2 . As shown, compared with the alternative techniques for amplification-free genomic analysis, such as gold nanoparticle microarrays and surface plasmon imaging 5 , CRISPR-Chip offers several advantages in a point-of-care context. CRISPR-Chip sample analysis is a three-step process (calibration, incubation and rinsing) that requires only a portable digital reader and reaction buffer, whereas other reported multi-step assay methodologies require multiple reagents and equipment 5, 6, [59] [60] [61] . CRISPR-Chip does not require genomic sample fragmentation, which is commonly achieved by sonication 5, 6 ; however, similar to other assay methodologies, it does require purification of the genomic sample. Rapid and portable DNA purification methods have been widely reported 62, 63 , suggesting that their upstream integration could yield a fully integrated whole genomic digital diagnostic that is more amenable to the point of care.
CRISPR-Chip sensitivity comes from the ability of the anchored dCas9 enzymes to rapidly scan the genome for its target sequence. This sensitivity could be further enhanced by optimizing the density of anchored dCas9 enzymes on the graphene surface. In addition, optimizing the graphene channel geometry and gFET operation parameters, such as voltage and frequency, could also enhance CRISPR-Chip sensitivity 64 . Furthermore, the addition of charged planar molecules, such as methylene blue, after the final rinsing step can enhance the CRISPR-Chip response at lower target concentrations 65 . An example of CRISPR-Chip signal enhancement utilizing methylene blue at a low concentration of the target DNA is shown in Supplementary Fig.  13 . Other amplification methodologies such as RPA, used in other CRISPR-based diagnostics technologies, could be utilized to increase the target sequence copy number before CRISPR-Chip analysis 11, 66 . This has the potential to expand the utility of CRISPR-Chip for the detection of infectious diseases, which often present low copy numbers in vivo. CRISPR-Chip could also be functionalized with other Cas proteins, such as Cas13a, for the detection of RNA-based target sequences 11 , further expanding its diagnostic potential. Lastly, CRISPR-Chip could not only improve access to genetic information with facile and early disease risk prediction and diagnosis, but it could also provide information about the affinity of sgRNA to various Cas enzymes via the observation of association/dissociation kinetics ( Supplementary Fig. 12 ). For example, CRISPR-Chip could be utilized as an optimization tool for validation and CRISPR complex formation efficacy prediction in various environments, designed to mimic a desired cellular target 67 . An example of real-time information that can be obtained by CRISPRChip is presented in Supplementary Fig. 11 . With the fast-expanding development of a broad range of CRISPR enzymes, such as newly developed MAD7 enzymes 68, 69 , CRISPR-Chip's utility as an affinity analysis tool is pertinent.
CRISPR-Chip is a promising tool, constructed from two propitious technologies-a graphene-based biosensor and CRISPR technology-and it has the potential to extend the boundaries of digital genomics. Future work invites more studies to enhance the capability of CRISPR-Chip to detect single nucleotide polymorphisms, which could significantly broaden its future clinical application.
Methods
Graphene-based FET sensor fabrication. Graphene chips were obtained from a commercial foundry (Cardea Bio). The chips were fabricated in several stages using conventional microelectromechanical systems processing 27 . The gFET was constructed according to published literature 27, 70 . Briefly, Ti/Pt source, drain and reference electrodes with corresponding bond pads were patterned on 6′ silicon wafers using a lift-off processing technique. Wafers were then cleaned by piranha etching to remove all potential organic residues that could act as dopants of the final graphene devices. High-quality graphene films grown on a copper foil substrate were spin coated with a poly methyl methacrylate support layer, then delaminated from the copper foil substrate by bubbling transfer 71 . The graphene films were then deposited on top of the electrode-patterned wafers and thoroughly cleaned with acetone and isopropanol. Graphene sheets were then patterned to form defined channels between the source and drain electrodes using plasmaenhanced chemical vapour deposition to deposit a silicon oxide layer over the entire wafer, and reactive ion etching to etch the graphene transistors 64 . Twoterminal electrical resistance characterization of the devices indicated a yield of >98% of functional graphene devices. The patterned graphene wafers were then diced into 9 mm × 9 mm dice and each chip was attached to a custom-printed circuit board package using epoxy. The circuit board was then encapsulated in epoxy, leaving an open cavity over the exposed graphene transistors for biological sample placement.
Measurement method. The CRISPR-Chip response is measured continuously utilizing a commercial reader (Agile R100; Nanomedical Diagnostics) and reported based on equation (1) . For this measurement, the liquid-gate voltage was swept between ±100 mV at a slow speed of 0.3 Hz, while V ds (the voltage applied across the drain and source electrodes) was held at 50 mV. The gate sweeping frequency mitigates the charge screening effect due to the non-specific adsorption of ions on the surface of the graphene 72, 73 .
Single-guide RNA design and evaluation. For bfp genomic analysis via CRISPRChip, the bfp-targeting sgRNA was designed and validated according to published literature 36 (see Supplementary Fig. 7 ). The bfp-specific sgRNA targeted the sequence GCTGAAGCACTGCACGCCATGG. For DMD analysis via CRISPRChip, two sgRNAs were designed and validated to target exons 3 and 51 of the human dystrophin gene by Thermo Fisher Scientific (TrueGuide and SS Oligo Design) and were ordered from Synthego and Invitrogen. The exon 3-targeting sgRNA (sgRNA-DMD3) targeted the sequence CTCTTCAGTGACCTACAGGA, whereas the exon 51-targeting sgRNA (sgRNA-DMD51) targeted the sequence CTTGGACAGAACTTACCGAC (Figs. 6b,c) .
Genomic samples for CRISPR-Chip analysis.
For bfp detection via CRISPRChip, target HEK-BFP and non-target HEK genomic materials lacking the bfp sequence were utilized. Briefly, HEK-BFP DNA was extracted from bfp-transduced HEK293T cells (PureLink Genomic DNA Mini Kit; Thermo Fisher Scientific) and purified (QIAquick PCR Purification Kit; Qiagen) according to the manufacturer's instructions and published protocol 36 . For analysis of DMD-associated mutations via CRISPR-Chip, human genomic samples from both healthy male and DMD male patients were purchased with certificate of analysis from the Coriell Institute for Medical Research. DMD samples presented in this study carried previously identified large-scale fragment deletions: A (NA07691) 44 , B (NA03780) 44 , C (NA03782) 44 , D (NA04100) 44 , E (NA05126) 44 and F (NA04364) 44 . Healthy samples-H1 (NA22264), H2 (NA22807) and H3 (NA03798)-were also validated for the presence of target exons (see Supplementary Fig. 14) . The concentration of genomic material was routinely measured before incubation with CRISPR-Chip using Nanodrop (Infinite M200 NanoQuant; Tecan).
CRISPR-Chip molecular linker functionalization and activation.
The CRISPRChip graphene biosensor, fabricated as described above, was cleaned twice with acetone and once with deionized water. Subsequently, it was functionalized by first incubating PBA (5 mM; 15 µl; Sigma-Aldrich) in dimethylformamide onto the graphene surface for 2 h at room temperature or overnight at 4 °C. The surface of the graphene sensor was then rinsed twice with dimethylformamide and once with deionized water and allowed to dry completely. The PBA was then activated using a 1:1 volume ratio of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (4 mM) and N-hydroxysuccinimide (11 mM) (Sigma-Aldrich) in 50 mM of 2-(N-morpholino)ethanesulfonic acid (pH 6) for 5 min at room temperature according to published studies 74, 75 before incubation with dCas9.
dCas9-sgRNA (dRNP) immobilization on the graphene surface. After PBA linker immobilization and activation on the surface of the graphene, 900 ng (30 µl in 2 mM MgCl 2 ) of dCas9 (University of California, Berkeley MacroLab) was incubated for 15 min at 37 °C on the surface of the graphene. The CRISPR-Chip I response was monitored continuously. Unreacted PBA molecules on the graphene surface were then blocked using amino-PEG5-alcohol (1 mM, 10 min at 37 °C) and ethanolamine hydrochloride (1 M, 10 min at 37 °C) (Sigma-Aldrich). After blocking, the graphene surface was washed with 2 mM MgCl 2 solution and incubated until the I response readings stabilized. To form the dRNP complex, 900 ng (30 µl in 2 mM MgCl 2 ) of sgRNA specific to the target sequence was introduced onto the graphene surface and incubated for 10 min at 37 °C to form dRNPs. sgRNA samples were thermally treated to remove the dimer structure before incubation with the CRISPR-Chip 76 . The CRISPR-Chip was then washed with 2 mM MgCl 2 for 5 min to remove any unbound sgRNA. This final step resulted in full dRNP formation on the graphene surface and a functional CRISPR-Chip.
CRISPR-Chip evaluation of bfp PCR products. dRNP-BFP-functionalized CRISPR-Chips were incubated with 1,800 ng of bfp PCR product (30 µl, 2 mM MgCl 2 ) for 30 min at 37 °C (see the section 'Genomic bfp PCR amplification'). As a negative control, the dRNP-Scram-functionalized CRISPR-Chip was incubated with 1,800 ng of bfp PCR product (30 µl, 2 mM MgCl 2 ) for 30 min at 37 °C. The sensor was rinsed (2 mM MgCl 2 , 30 µl) for 15 min at 37 °C after incubation with the dsDNA sample. The I response was continuously monitored.
Affinity of dRNP-BFP-functionalized MBs to HEK-BFP. MBs (1 µm; Dynabeads MyOne Carboxylic Acid; Invitrogen) were functionalized with dRNP-BFP to evaluate the dRNP-BFP complex's affinity to target sequences contained within whole genomic samples. Briefly, carboxylated MBs were activated using N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (26 mM in 10 mM potassium phosphate, 0.15 M NaCl) and sulfo-N-hydroxysuccinimide (23 mM in 10 mM potassium phosphate, 0.15 M NaCl) according to the published protocol 77 . Activated MBs were promptly coupled with dCas9 (33.3 ng µl −1 in 10 mM potassium phosphate, 0.15 M NaCl) for 3 h. After dCas9 coupling, MBs were blocked for 30 min at room temperature using glycine (1.0 M). ) for 1 h at 37 °C. For control experiments, HEK DNA was also incubated with the MB-dRNP-BFP complex. After magnetic separation, the supernatant was eluted and evaluated using gel electrophoresis (100 V for 1.5 h). Example gel images are presented in Supplementary Fig. 10 . The intensities of the bands were quantified with ImageJ (National Institutes of Health). The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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